January 23, 2020 - MEDITEST announces its rapprochement with the company IBA Dosimetry on the French radiotherapy market.
IBA Dosimetry innovates in radiotherapy, proton therapy and diagnostic imaging thanks to quality, independent and integrated insurance solutions which are effective, intuitive and which ensure the peace of mind of health professionals and patients around the world.
MEDITEST becomes the exclusive distributor and service partner for the entire IBA range on the French market. In particular the new SmartScan ™ solutions, the Myqa® global platform or the Myqa® Daily Morning solution. MEDITEST thus intends to respond to all the problems and needs in dosimetry applied to radiotherapy.
The partnership will be beneficial for all customers or future customers MEDITEST E and IBA and members of the French Radiotherapy Community, thanks to the complementarity of product and services ranges.
With IBA, MEDITEST wishes to continue a common course to improve patient safety and the performance of quality insurance solutions in radiotherapy.
About Iba Dosimetry:
IBA Dosimetry GmbH innovates in radiotherapy, proton therapy and diagnostic imaging thanks to independent and integrated quality insurance solutions which are effective, intuitive and which ensure the peace of mind of health professionals and patients around the world. The Myqa® Global QA platform is the backbone of quality insurance solutions. IBA Dosimetry has more than 220 employees worldwide and is located in Germany, France, China and the United States. IBA Dosimetry is part of the IBA group, a global medical technology company which focuses on the implementation of integrated and innovative solutions for the diagnosis and treatment of cancer. More information on: www.iba-dosimetry.com